Although olfactory neurons are not directly infected by SARS-CoV-2, they do sustain significant damage from the infection of neighboring cells.
Category: pharma & healthcare
What You Should Know About Traumatic Brain Injury
Bob Saget, beloved actor, comedian and father, died on January 9th, 2022 at age 65 from blunt head trauma, resulting in a severe and fatal traumatic brain injury.
Canadian Physicians Can Now Prescribe Nature To Patients
Time spent in nature has been shown to have numerous benefits to physical and mental health.
Quantum Leap In Newborn Whole Genome Sequencing
Stanford scientists have discovered an improved method of genome sequencing that can diagnose a rare genetic disorder within the span of just eight hours.
Good News: Full Vaccination Protects Against Omicron Hospitalization And Death
Three doses provide some protection from infection, but that protection wanes over four to six months to a very low level. The good news is that two or three doses of currently-available vaccines provide excellent protection against severe disease lead…
Covid Infection During Pregnancy: What Are The Risks?
Although pregnant women are not more likely to contract the virus, infected mothers have an increased risk of severe disease and premature delivery.
EQRx Seeks To Establish A More Competitive Market For Oncology Drugs In The U.S.
EQRx aims to bring new medicines to market at what it states will be “radically lower” prices. The company is hoping to disrupt the cancer immunotherapy market and take on blockbuster drugs, such as Keytruda.
Canada’s Hockey Team Play Entire Olympic Match With Masks On After Delayed Covid-19 Tests
Late Covid-19 testing results led to both teams wearing N95 masks on the ice after a one hour delay to the game.
Young Americans Are Dying At Higher Rates Than In Any Other Wealthy Country
Young people in the U.S. are less likely to make their 25th birthday than in any other high-income country, with poverty, gun crime and violence major causes.
Aduhelm’s Paltry $1 Million In Q4 Sales Indicates CMS’s Coverage With Evidence Development May Be Biogen’s Only Chance At Salvaging Something From The Product
Medicare’s controversial draft decision – released on January 11th of this year – to restrict coverage of Aduhelm to beneficiaries who enroll in post-marketing clinical trials may be the only feasible option left for the product. Such a policy is calle…
